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ABSTRACT 
Aging is the largest single risk factor for intervertebral disc degeneration (IDD). Dysregulated 
disc cells are thought to drive age-associated disc proteoglycan (PG) loss, a hallmark of IDD, 
through a combination of reduced capacity to synthesize matrix PG and increased production of 
proteolytic enzymes to breakdown matrix.  The link between aged degenerative discs and 
cellular senescence has been previously observed in human discs, but it remains unknown if 
senescent disc cells are phenotypically different from their non-senescent counterpart in terms of 
matrix homeostasis. Hence, the goal of this study is to explore matrix homeostasis characteristics 
of senescent disc cells.  
Outcome measures for anabolism have established that stress-induced senescence of 
human disc cells resulted in decreased PG synthesis, increased collagen type II expression in 
nucleus pulposus (hNP), and decreased collagen type I expression in annulus fibrosis (hAF).  
For catabolism, Western analysis revealed greater levels of ADAMTS- and MMP-generated 
proteolytic aggrecan fragments as a result of cleavage in the aggrecan interglobular domain 
(IGD) in the conditioned media (CM) of H2O2–induced senescent hNP cells compared to control.  
In contrast, the levels of aggrecan IGD proteolytic fragments were relatively unchanged in the 
CM of senescent hAF cell culture compared to non-senescent hAF cell culture. ELISA and 
antibody array experiment showed elevated levels of many pro-inflammatory cytokines (IL-6, 
IL-8, PDGF-BB, GCSF), chemokines (EOTAXIN-2, IP-10, RANTES) and MMPs (MMP-1, 
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MMP-3, MMP-10) in the CM of senescent hNP cells.  These are key factors previously reported 
for senescence-associated secretory phenotype (SASP) of stress-induced senescent cells which 
impart profound catabolic effects on neighboring cells and the extracellular matrix.  The total 
GAG content moderately decreased in senescent hAF and significantly decreased in senescent 
hNP cell cultures compared to non-senescent cell culture control.  
These in vitro findings suggest that senescent disc cells perturb extracellular matrix 
homeostasis via acquisition of SASP, reduced matrix synthesis capacity, and increased matrix 
degradation. Identifying and confirming cellular senescence as a driver of disc PG loss and IDD 
will offer novel opportunities for targeted therapy to prevent or treat IDD, which would have a 
tremendous public health impact in preventing or ameliorating chronic low back pain.  
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1.0  INTRODUCTION 
1.1 INTERVERTEBRAL DISC DEGENERATION (IDD) 
1.1.1 Disc Biology 
The intervertebral disc (IVD) is a fibrocartilaginous structure (Figure 1) surrounded by 
longitudinal ligaments laterally and vertebrae axially. The IVD is sandwiched between cartilage 
endplates (CEPs), which contain the ends of capillaries from the vertebral vascular network 
important for delivering nutrients to the disc [1, 2]. Disc annulus fibrosis (AF) consists of mostly 
collagen type I fibers surrounding the proteoglycan-rich gelatinous nucleus pulposus (NP). The 
NP contains randomly organized collagen type II fibers, elastin fibers, with sparsely interspersed 
notochordal and chondrocyte-like cells [3, 4]. The AF consists of 15-25 concentric rings 
(lamellae) with 60-degrees-to-vertical positioned parallel collagen fibers.  Embedded within each 
ring are elongated, fibroblast-like cells positioned parallel to the collagen fibers [3, 5].  
During the transition from outer AF to inner AF and NP, there is less collagen type I and 
more collagen type II [6, 7]. Mechanically, the AF acts to withstand the tensile strain while the 
NP counteracts compressive force in the spine [8, 9]. Thus IVDs serve to bear load and provide 
flexibility to the spine.  
   
 2 
The high proteoglycan (PG) content in the NP attracts counterions from the negatively 
charged sulfates on the chondroitin- and keratan-sulfate glycosaminoglycan (GAG) sidechains 
on PG (Figure 1), generating high osmotic gradient and imbibing a large amount of water, which 
enables to the NP to resist compression. Matrix homeostasis, a proper balance of matrix 
catabolism and anabolism, is essential for the functional health of the disc.  Disc matrix 
catabolism involves the breakdown of the extracellular matrix typically mediated by A 
Disintegrin And Metalloproteinase with Thrombospondin Motifs (ADAMTSs), and Matrix 
Metalloproteinases (MMPs).  Disc matrix anabolism is determined principally by synthesis of 
the two major classes of disc structural matrix constituents, collagens, and proteoglycans (Figure 
2).  The main proteoglycan in disc NP tissue is aggrecan. 
Development and remodeling of the disc depend on the disc cells’ ability to synthesize 
new matrix and degrade existing matrix by secreting proteases (ADAMTSs and MMPs), the 
products of which can be detected with molecular markers (more abundant during development 
before adulthood) [8, 10-17]. During transition to adulthood, the NP composition undergoes 
changes, including an increase in collagen content resulting in a texture and consistency change 
from translucent liquid to soft, gelatinous tissue.   
The NP contains the maximum PG amount during the young adult phase, followed by 
progressive PG decline with age [8]. This remodeling process during development may 
contribute to the varied compressive loads that adult discs can handle (between 2.8 and 13.0 
kiloNewtons (kN)) [8, 18]. 
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This sketch represents the anatomy of the intervertebral disc (IVD) and surrounding structures. A 
functional spinal unit (FSU) consists of vertebrae, IVD, facet joints, and ligaments. ISL and SSL: Interspinous and 
Supraspinous Ligaments, which are posteriorly positioned between the spinous processes (function to protect 
nerves). FC: Facet Cartilage (composed of hyaline cartilage) makes up facet joints along with joint capsule, 
synovium, and synovium fluid. CEP: Cartilage Endplate connects the IVD to vertebral body. NP: Nucleus Pulposus 
(gelatinous center of the IVD surrounded by AF).  AF: Annulus Fibrosis (outside NP-surrounding structure of the 
IVD). Adopted with permission from Dr. Robert Hartman. 
Figure 1. Structural components and organization of the intervertebral disc and functional spinal unit. 
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The components of a disc proteoglycan aggregate include proteoglycan, hyaluronic acid (HA), and link 
protein (LP).  Proteoglycan binds noncovalently to HA, and this interaction is mediated by LP.  A disc proteoglycan 
unit consists of the core protein aggrecan to which glycosaminoglycans such as chondroitin sulfate and keratan 
sulfate are covalently attached.  G1, G2, G3 are globular, folded regions of the central core protein aggrecan [9]. 
Known cleavage sites of proteases ADAMTSs and MMPs on aggrecan [19, 20]. CS1 and CS2: Chondroitin Sulfate 
attachment domains 1 and 2. KS: Keratan Sulfate. LP: Link Protein. 
Figure 2. Structural components and organization of aggrecan. 
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1.1.2 IDD Features 
Intervertebral disc degeneration (IDD) has been defined as the abnormal, cell-mediated process 
of progressive loss of PG matrix and eventual failure of the disc structural integrity [8]. IDD 
leads to many biochemical and mechanical changes in the IVD, which interferes with the natural 
function of the spine. Early characteristics of IDD include loss of PG and water content of the 
NP due to matrix homeostatic imbalance.  Late stage macroscopic changes associated with IDD 
include annular fissure, collapse of disc height, and formation of neo-osteophytes in the adjacent 
cartilaginous endplate and vertebrae.  IDD is associated to pathological conditions such as disc 
herniation, low back pain, and spinal stenosis (narrowing of the spinal canal leading to pressure 
on the spinal cord). There are many influencing factors involved in IDD, including genetic 
predisposition, impaired nutrient supply, changed enzyme activity level, cellular senescence and 
apoptosis, changes in matrix and water content, failure of structural integrity, and neurovascular 
ingrowth [8, 21]. 
1.1.3 Current IDD Therapies 
Many patients with IDD and LBP have resolution of their pain with conservative treatments such 
as medications (nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, muscle 
relaxants [22-24]) and physical therapy [22, 25, 26]. The traditional, archaic prescription of bed 
rest has actually shown to be less effective than physical activity for recovery due to muscle 
deconditioning [22, 27]. If conservative treatments fail after 6 to 12 weeks [22, 28], current 
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medical interventions for IDD mainly are surgeries with the goals of removing potential pain 
generating sources and restoring natural supportive disc functions for everyday motions.  
Current biologic strategies for IVD regeneration have been focused on mainly cell-based 
approaches with and without tissue-engineered scaffold. The primary goal of these therapies is to 
increase the net ECM content in the disc. There has been less of an emphasis of the effect of 
these therapies on potentially depleting the disc nutrient supply, which is thought to drive IDD 
[2, 8]. The IVD is the largest avascular tissue in the body which creates a hypoxic environment 
with decreasing oxygen concentration gradient from the outer AF to the inner NP [29]. Nutrient 
supply to the NP cells specifically is quite limited due to the lack of a vascular supply with the 
capillaries ends reaching to only the CEP. The balance of anabolism and catabolism by the IVD 
cell population is maintained in a healthy disc, however during IDD, degradation may overtake 
synthesis of ECM components causing a net loss of matrix and thus drives disc degeneration 
[30].  
A potential harmful effect of cell-based therapies is the introduction of additional demand 
on the limited level of nutrients in native discs with the newly introduced mesenchymal stem 
cells (MSCs) without increasing the supply of nutrients [2], which may limit long term 
effectiveness of such therapies due to nutrient starvation. In degenerated discs, the chronic state 
of inflammation may increase the glucose consumption and lactic acid production rates resulting 
in an increased cellular nutrient demand with reduced supply (transport rate) into the degenerated 
disc [2, 31, 32].   
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Therefore, this evidence points towards an overall reduced nutrient availability for the disc cells 
either due to reduced transport rate of nutrients or increased cellular demand.  Thus, cell-based 
therapies to treat IDD have to take into consideration the disc limited nutrient environment. 
1.2 LOW BACK PAIN AND IDD 
Low back pain (LBP) is the second leading cause for a patient consulting a physician in the US, 
just behind upper respiratory infections [33]. About 80% of the US population will experience 
back pain during their lifetime [34] while greater than 25% of Americans experience LBP 
annually [35]. These LBP patients experience a drastic decrease in the quality of life due to 
chronic pain and restricted mobility. With LBP, there is a large economic burden from the 
socioeconomic cost of the direct medical costs (and non-health care associated costs – food, 
travel, etc.) as well as the indirect costs due to reduction of employment and household 
productivity. The total of these socioeconomic costs exceeds $100 billion in the US [36]. 
Intervertebral disc degeneration (IDD) is the leading underlying causative factor of LBP. 
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1.3 AGING AND IDD 
1.3.1 Aging Drives IDD 
There are several proposed causes of IDD, including genetic predisposition, overloading-induced 
injury of the IVD, smoking, and aging. Of these, aging is the biggest etiologic factor because 
disc matrix PG is invariably and progressively lost with age [37, 38]. How aging disrupts disc 
matrix homeostasis leading to PG loss and IDD is not clearly understood.  Hence, understanding 
the biology of disc aging is critical in developing effective therapeutic interventions to delay and 
or treat age-related IDD disorders.  This is imperative because of the growing aging population 
which is expected to bring great burdens and challenges from the many age-related diseases.  By 
2050, the world population is predicted to be comprised of 1.5 billion of ages 65 and older 
compared to 524 million in 2010 [39, 40]. 
1.4 CELLULAR SENESCENCE AND AGING 
1.4.1 History of Cellular Senescence 
The biological purpose for senescence has been thought to be similar to apoptosis, which is to 
prevent the proliferation of or eliminate undesired, damaged cells that are now harmful to the 
host [41]. Senescent cells are the opposite of cancer cells in terms of their respective proliferative 
properties. The activation of cyclin-dependent kinase (CDK) inhibitors p16, p15, p21, p27 is the 
converging point of all senescence-inducing stimuli, which ultimately resulting in hypo-
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phosphorylation of retinoblastoma (RB) and  termination of proliferation [41-46]. After 
experiencing stressful stimuli, the cell decides whether to attempt self-repair to continue dividing 
or undergo senescence to stop dividing as a mechanism of preventing tumor formation from 
accumulated cellular damage. Senescence is initiated acutely with the likes of IL-1α followed by 
the establishment of the Senescence-Associated Secretory Phenotype (SASP) with the secretion 
of cytokines and chemokines, which recruit immune cells with the purpose of clearance of the 
damaged cell [47]. However, it is proposed that the rate of immune clearance of senescent cells 
is eventually outpaced by the accumulation of senescent cells with age. This occurs even with the 
potential attenuation of SASP with microRNAs such as mir-146a and mir-146b, which drives 
aging in cells, tissues, and ultimately the host [47, 48].  
1.4.2 Cellular Senescence as a driver of Aging 
Senescence was initially discovered by Leonard Hayflick and Paul Moorhead who observed that 
human fibroblasts have a limit on their proliferative capacity, and subsequent studies associated 
cessation of cell proliferation with telomere shortening [41].  Such replicative cell senescence 
was then thought to be a protective mechanism against tumorigenesis.  However growing 
evidence now suggests that cellular senescence as a key driver of organismal aging.   Senescent 
cells have been found to be increased in aged and diseased tissues in age-associated 
comorbidities such as Alzheimer’s disease [49, 50], Parkinson’s disease [51], glaucoma [52], 
atherosclerosis [53, 54], COPD [55-58], osteoarthritis [59-62], Type 2 diabetes [63, 64], and 
cancer [65, 66] in elderly.  Stress-induced senescent cells have been shown to acquire 
senescence-associated secretory phenotype (SASP) which result in the increased production and 
secretion of pro-inflammatory cytokines, chemokines, growth factors, and matrix 
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metalloproteinases (MMPs) including IL-6, IL-8, MMP1, and MMP3 [67].  Importantly, 
clearance of senescent cells is reported to delay age-associated disorders in a progeroid mouse 
model [68-71]. Therefore, elucidating mechanisms of senescence may provide new therapeutic 
strategies to delay age-associated comorbidities, which would have a profound public health 
impact by attacking many chronic diseases early on by limiting the most critical risk factor of 
aging. 
1.4.3 Therapeutic Strategies to eliminate Cellular Senescence 
Two possible therapeutic strategies for targeting senescence are interfering with signaling 
pathways that result in senescence-associated cell cycle arrest and targeting SASP to minimize 
harmful effects [40]. Inhibiting proliferation arrest via interfering with the signaling pathways 
(p16, Rb, p53) may have unintended effects such as the loss of tumor surveillance mechanisms 
for preventing cancer. Prevention of the chronic development of SASP may provide a balance of 
senescence with preservation of its four functions of tumor suppression, tumor promotion, aging, 
and tissue repair while limiting the “harmful” functions [47].  
Another therapeutic strategy for many chronic diseases is the targeted removal of 
senescent cells, themselves are the underlying source of chronic state of inflammation, with the 
goal of restoring function to tissues [68]. Of course, the caveat would be identifying a specific 
marker of senescent cells to selectively target them for removal. Those individuals living to 100 
years of age or older (centenarians) have been observed to have low levels of senescent CD8+ 
CD28- T cells that may indicate preserved immune function [72, 73].  
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Thus the removal of senescent cells may enhance the innate and adaptive immune responses of 
the elderly extending lifespan while improving quality of life (via restoring some tissue 
functionality) leading to reduced socioeconomic burden via limiting tertiary prevention 
healthcare costs [68].  
1.4.4 Cellular Senescence in Disc 
Cellular senescence has been previously noted as accelerated in aged, degenerated discs 
compared to healthy discs both in humans and animals [74, 75]. These senescent cells have also 
been associated with increased catabolism, which supports the hypothesis that cellular 
senescence is a potential driver of IDD. The percentage of senescent and proliferating cells has 
been compared in human AF in vivo with the observations of increased senescent cells in 
degenerated discs compared to control discs [75] and low cell proliferation in both young and  
degenerated discs.  However, whether senescent disc cells are a causative driver of age-related 
IDD and how they do so are important questions which have not been addressed.  
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2.0  OBJECTIVE 
2.1 HYPOTHESIS 
Aging is the largest risk factor for IDD, which is a condition that contributes to many debilitating 
spinal disorders and disabilities with a tremendous socioeconomic burden [76].  Loss of disc 
matrix proteoglycan (PG) is a hallmark of age-related IDD as a consequence of perturbed matrix 
homeostasis, a combination of cell-mediated changes in PG synthesis (decreased) and PG 
proteolysis (increased) [1]. Although elevated levels of senescent disc cells have been linked to 
IDD in aged discs, the phenotype and characteristics of senescent disc cells have not been 
explored.  Based on the reported findings in the literature, I hypothesized that senescent disc 
cells acquire imbalanced matrix homeostasis which drives age-related loss of matrix PG leading 
to IDD.  I propose to test this central hypothesis with the following specific aims.  
2.2 SPECIFIC AIMS 
Aim 1: To test the hypothesis that senescent human disc cells perturbs matrix homeostasis 
by decreasing the anabolism of the disc matrix.  
Aim 2: To test the hypothesis that senescent human disc cells perturbs matrix homeostasis 
by increasing the catabolism of the disc matrix.  
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Approach. 
Induction and confirmation of senescence. Human disc cells isolated from surgical 
specimens were exposed to hydrogen peroxide treatment twice using the previously established 
oxidative induction of senescence method treatment [77]. Senescence phenotype was verified by 
assaying for the SASP, senescence-associated β-galactosidase (SA β-gal) staining for SA β-gal 
activity, brightfield microscopy for cell morphology, trypan blue exclusion assay for cell 
proliferation.  
Matrix Anabolism. To assess matrix anabolism, the oxidative stress-induced senescent 
human NP and AF cells were measured for their total glycosaminoglycan (GAG) content by the 
DMMB colorimetric assay and normalized to total cell number or DNA amount by Picogreen 
assay. Quantitative RT-PCR was performed to assess the relative gene expression of matrix 
structural components: Aggrecan, Collagen 1, Collagen 2, Versican, and Link Protein.  
Matrix Catabolism. Western blotting was performed to assess the ADAMTS- and MMP-
generated catabolic degradation of aggrecan proteins. SASP profile was determined using 
inflammation and MMP antibody arrays (40 targets and 10 targets, respectively) to assess levels 
of other inflammatory proteins that senescent hNP or hAF cell may produce and secrete. To 
assess the active state of secreted MMPs, MMP enzymatic activity from the conditioned media 
was measured. 
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3.0  MATERIALS AND METHODS 
 
Figure 3. Overall experimental design 
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3.1 SAMPLE COLLECTION AND CELL ISOLATION 
Human AF and NP samples were obtained from surgical specimens (Table 1) from generally 
older 47.7 ± 11.4 years (mean ± SD) patients with diagnoses of stenosis or herniated disc 
generally (Figures 3 and 4). These tissue samples were washed, minced, and digested in 0.2% 
pronase (EMD Chemicals 53702) for one hour then 0.02% collagenase P (Roche Applied Science 
11213873001) overnight. The following day these cells were filtered and then plated onto tissue 
culture-treated flasks. 
Table 1. De-identified patient information 
Age Sex Diagnosis Disc  Level 
Degen.  
Grade Smoker 
Diab- 
etic 
Outcome  
Measures 
56 M 
Cervical 
Stenosis 
C5-6, 
C6-7 2 Yes N/A ELISA 
59 F 
Cervical 
Stenosis 
C3-4,  
C4-5 3 Yes N/A ELISA 
49 M 
Cervical 
Stenosis 
C5-6,  
C6-7 3 Yes N/A ELISA 
44 M 
Cervical Disc  
displacement 
C5-6,  
C6-7 2 No N/A ELISA 
40 F Herniated Disc C6-7 2 Yes N/A Ab Arrays 
48 F Herniated Disc 
C5-6,  
C6-7 2 Yes N/A 
PCR 
Catabolic 
68 F 
Cervical 
Stenosis C6-7 3 No N/A 
PCR 
Catabolic 
53 F 
Cervical 
Stenosis 
C4-5, 
C5-6 2 No N/A 
PCR 
Catabolic 
33 F 
Cervical 
Stenosis 
C5-6, 
C6-7 3 Yes N/A Ab Arrays 
56 M 
Cervical 
Stenosis 
C3-4, 
 C4-5 2 Yes N/A 
PG 
Synthesis 
48 M 
Cervical 
Stenosis 
C5-6, 
C6-7 3 Yes N/A 
PG 
Synthesis 
60 F Scoliosis L5-S1 3 Yes N/A 
PG 
Synthesis 
46 F 
Cervical 
Stenosis 
C4-5, 
C5-6 Unknown Yes N/A Ab Arrays 
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32 F Non-Union L4-5 2 Yes N/A Ab Arrays 
38 M 
Cervical 
Stenosis 
C5-6, 
C6-7 2 N/A N/A 
PCR 
Catabolic 
45 F Cervical Stenosis C4-C7 2 No N/A 
PCR 
Anabolic,  
PCR 
Catabolic 
54 F spondylotic stenosis 
C5-
C6,  
C6-C7 
2 No No 
PCR 
Anabolic,  
PCR 
Catabolic 
56 M spondylotic stenosis 
C5-
C6, 
C6-C7 
2 No No 
PCR 
Anabolic,  
PCR 
Catabolic 
55 F 
cervical stenosis  
and 
radiculopathy 
C5-
C6,  
C6-C7 
3 No No PCR Catabolic 
28 F lumbar stenosis 
L4-
L5,  
L5-S1 
2 No No PCR Anabolic 
52 M herniated disc C4-C6 3 No No 
PCR 
Anabolic, 
GAG, 
Western 
21 M cervical stenosis 
C3-
C4,  
C4-C5 
2 No No 
PCR 
Anabolic, 
GAG, 
Western 
57 F cervical stenosis C5-C7 3 No No GAG, Western 
 
Table 1. Continued 
 
   
 17 
 
Figure 4. Detailed experimental protocol for tissue processing and disc cell isolation 
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3.2 INDUCTION AND CONFIRMATION OF CELLULAR SENESCENCE 
To induce cellular senescence and SASP (Figure 5) by oxidative stress, we used the previously 
established hydrogen peroxide treatment at normoxic culture conditions (atmospheric 20% O2) 
[77]. Greater number of cells (two fold that of untreated control: 50,000 cells (Figure 5)) were 
treated with 500 µM hydrogen peroxide in F-12 10% FBS 1% PS for two hours then changed to 
regular media F-12 10% FBS 1% PS (Life Technologies 11765-062, Atlanta Biologicals S12450, 
Life Technologies 15140-16), split onto new plates and incubated overnight at 37°C and 
normoxic culture conditions, treated again with 500 µM hydrogen peroxide in F-12 10% FBS 
1% PS for two hours (Life Technologies 25300-120), changed to fresh regular media F-12 10% 
FBS 1% PS, and incubated at 37°C and normoxic culture conditions for 4 days followed by 
sample collection to allow enough time for the development of SASP (Figure 5).   
Senescence-associated β-galactosidase (SA β-gal) staining  [78] was done after the above 
treatment in 12 well plates by washing the cells with PBS then fixing with 2% paraformaldehyde 
(Sigma-Aldrich P6148) and 0.2% gluteraldehyde (Sigma-Aldrich G5882) for 5 minutes.  This 
was followed by a PBS wash and overnight incubation with a staining solution: 40 µL 1M 
Magnesium Chloride (Sigma-Aldrich M8266), 600 µL 5M Sodium Chloride (Sigma-Aldrich 
S3014), 2 mL100mM Potassium Ferrocyanide (Sigma-Aldrich P3289), 1 mL 20 mg/mL X-gal 
(Sigma-Aldrich B4252) in dimethylformamide (Sigma-Aldrich D4551), 4 mL 0.2M Citric 
Acid/Dibasic Sodium Phosphate Buffer (Sigma-Aldrich 251275), 12.4 mL Water). Images were 
taken using brightfield microscopy at 40X magnification.  
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Figure 5. Detailed experimental protocol for cell culture, treatment with hydrogen peroxide, and sample 
collection for different outcome measures. 
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3.3 MATRIX ANABOLISM: PROTEOGLYCAN SYNTHESIS AND GENE 
EXPRESSION 
To characterize PG metabolism, PG synthesis was measured by 35S-sulfate (American 
Radiolabeled Chemical ARS-105) incorporation by adding radiolabeled media to the cells for 2 
to 3 days followed by adding homogenization buffer containing 200 mM Sodium Chloride, 50 
mM Sodium Acetate, 0.1% Triton X-100 (Sigma-Aldrich X-100), 10mM EDTA, 50 µM DTT 
(Sigma-Aldrich D9779), and 1x Protease Inhibitor (Sigma-Aldrich P8340) to each well at 4 °C 
for 1 hours with shaking. Next, in a separate 1.5 mL microcentrifuge tube, the homogenization 
buffer is then added to a Guanidine Hydrochloride extraction buffer containing 8M Guanidine 
Hydrochloride (Sigma-Aldrich G3272), 50mM Sodium Acetate, 10mM EDTA, and 1x Protease 
Inhibitor at 4 °C for 4 hours with shaking to extract proteoglycans [79]. The processed samples 
in homogenization and GHCl were mixed with Alcian Blue solution containing 0.02% Alcian 
Blue (Sigma-Aldrich A9186), 50mM Sodium Acetate, and 85mM Magnesium Chloride. for an 
hour at room temperature then loaded onto nitrocellulose membranes (Millipore HAWP 025 00) 
and washed with a buffer containing 100 mM sodium acetate (Sigma-Aldrich S2889), 50mM 
magnesium chloride, and 50mM sodium sulfate (Sigma-Aldrich 239313) to eliminate the 
unincorporated 35S-sulfate. The membranes were dissolved in scintillation fluid (National 
Diagnostics LS-201) and the counts per minute (CPM) are detected with the scintillation counter 
(Packard Tri-Carb 2100TR). CPM was converted to number of pmoles of sulfate, using the 
specific activity of 35S-sulfate in the conditioned media, and then normalized to DNA amount via 
Picogreen assay (Life Technologies P7589).  
RNA isolation was done using Qiagen RNeasy Plus Micro Kit (Qiagen 74034). 
Quantitative RT-PCR was performed using a one-step SYBR Green fluorescent reporter system 
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(Bio-Rad 1725151) with Bio-Rad iQ5 Multi-color Real-time PCR Detection System with 7 
cycles: Cycle 1 (30 minutes @ 48º C), Cycle 2 (10 minutes @ 95ºC), Cycle 3 (15 seconds @ 
95ºC then 1 minute @ 62ºC, repeated 30X), Cycle 4 (1 minute @ 95ºC), Cycle 5 (1 minute @ 
55ºC), Cycle 6 (10 seconds @ 55ºC, repeated 80X), Cycle 7 (hold indefinitely @ 22ºC). 
Previously validated primers [80, 81] were used for key matrix components: Aggrecan, Collagen 
1, Collagen 2, Versican, and Link Protein (Table 2). 30 ng of RNA per sample were analyzed. 
Melt curves were analyzed (Cycle 6) after amplification was complete and compared to RNA-
negative water controls.  For all experiments performed, there were either no products from the 
water control as signified by no peak or a non-specific primer dimer product that appeared as a 
distinct peak at a lower temperature shifted down from the specific cDNA products. The 2ΔΔCt 
approximation method [82] was used for relative mRNA quantification for the specific products 
probed for in Table 1. The amplification efficiencies of the reference housekeeping gene and the 
target gene of interest must be approximately equal for this method to be valid.   
Initially, GAPDH was used as a reference housekeeping gene for normalization of all 
other genes of interest in the 2ΔΔCt approximation method. Untreated, negative control samples 
were used as the calibrator sample for normalization for all other samples of interest in the 2ΔΔCt 
approximation method.  
Table 2. Primers used for qRT-PCR for matrix anabolism and matrix catabolism 
Gene  
[Homo 
sapiens 
(human)] 
Forward (5' to 3')  Reverse (5' to 3') 
ADAMTS-
4 TCACTGACTTCCTGGACAATGG ACTGGCGGTCAGCATCATAGT 
ADAMTS-
5 CTGACCTACCACGAAAGCAGATC ATGCCGGACACACGGAGTA 
Aggrecan AAGAATCAAGTGGAGCCGTGTGTC TGAGACCTTGTCCTGATAGGCACT 
Collagen 
Type I, α1 GGAAACAGACAAGCAACCCAAACT GGTCATGTTCGGTTGGTCAAAGATAA 
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Collagen 
Type II, α1 
ATGACAATCTGGCTCCCAAC GAACCTGCTATTGCCCTCCTG 
GAPDH ACCCACTCCTCCACCTTTGAC TCCACCACCCTGTTGCTGTAG 
HAPLN1 GeneCopoeia Catalog#: HQP003013 Validated All-in-One™ qPCR Primer 
IL-6 AGCCACTCACCTCTTCAGAACG TGCCTCTTTGCTTTCACAC 
IL-8 GGCCGTGGCTCTCTTGGCAG TGTGTTGGCGCAGTGTGGTCC 
MMP-1 GAGCTCAACTTCCGGGTAGA CCCAAAAGCGTGTGACAGTA 
MMP-3 CAAGGAGGCAGGCAAGACAGC GCCACGCACAGCAACAGTAGG 
TIMP-1 TGGCTTCTGGCATCCTGTTGTTG CGCTGGTATAAGGTGGTCTGGTTG 
TIMP-3 AGGACGCCTTCTGCAACTC GTACTGCACATGGGGCATCT 
Versican GCGGAGACCAGTGTGAACTTGATT ACATAACTTGGAAGGCAGAGGCAC 
3.4 MATRIX CATABOLISM: GENE EXPRESSION 
RNA isolation was done using Qiagen RNeasy Plus Micro Kit. Quantitative RT-PCR was 
performed using a one-step SYBR Green kit (master mix and reverse transcriptase) with 
validated primers for MMPs, ILs, and ADAMTSs (Table 1). ELISA was performed with the 
conditioned media from 4 day incubation after the second hydrogen peroxide treatment of the NP 
cells using R&D Total Human IL-6, IL-8, MMP1, and MMP3 DuoSets (R&D Systems DY206, 
DY208, DY901, DY513). 
3.5 MATRIX CATABOLISM: PROTEIN ARRAYS AND INFLAMMATION/MMP 
ARRAYS 
Antibody arrays and western analyses were performed using concentrated conditioned media 
from human AF and NP cells with and without hydrogen peroxide oxidative stress treatment. 
Conditioned media was concentrated 3-5X using Millipore Amicon Ultra-15 Centrifugal Filter 
Table 2. Continued 
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Unit with Ultracel-3 (EMD Millipore UFC900308) membrane with 3 kDa molecular weight cut 
off – proteins smaller than 3 kDa excluded. For detection of aggrecan fragments, 1:1000 rabbit 
polyclonal anti-Aggrecan antibody (Abcam ab36861) was used as primary antibody followed 
with 1:10000 anti-rabbit goat secondary antibody with HRP (Thermo Scientific PI-31460) and 
chemiluminescent detection (Thermo Scientific 34096 and Bio-Rad ChemiDoc MP). Western 
was performed using Tris-HEPES 4-20% gradient gel (Thermo Scientific 25204), Tris-HEPES-
SDS Running Buffer (Thermo 28398), Tris-Glycine Transfer Buffer with 10% Methanol 
(Thermo Scientific 28380, Fisher Scientific A452-4), and TBST (Sigma-Aldrich T9039).  
Antibody arrays were performed using human inflammation antibody array (RayBioTech AAH-
INF-3-4) and human MMP antibody array (RayBioTech AAH-MMP-1-4) based on 
manufacturer’s protocol instruction. 
3.5.1 MMP Enzymatic Activity assay 
Detection of a fluorogenic substrate cleavage product was used to assess MMP enzymatic 
activity [83]. Samples normalized to total protein were in serum free, phenol red free DMEM/F- 
12 (Life Technologies 11039-021) media (SF PF media). The stock substrate XI (AnaSpec 
60578-01) was dissolved in 60 µL DMSO. The substrate working solution was prepared in a 
1:50 dilution with 100 mM HEPES (Sigma-Aldrich H4034) in SF PF media.  Seventy-five 
µL of each sample or media control was added to each well in duplicate in a black 96-well plate 
(CoStar 07- 200-590).  Twenty- five µL of the substrate working solution was added to each 
well. Fluorescence was measured at 490nm excitation/520nm emission every 5 minutes for 1 
hour. The resulting signal (after blank subtraction) is the Cleavage Product Fluorescence (CPF).  
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The slope for the linear regression line with y-intercept = 0 was calculated for CPF vs. time 
(min) each sample. The slopes were averaged for each duplicate. The slopes have the unit of mM 
fluorescent product/min, representing the MMP enzymatic rate. 
3.6 TOTAL MATRIX CONTENT: DMMB GAG ASSAY 
Colorimetric GAG (DMMB) assay was used to quantify total matrix content from ECM 
digestion buffer: 1mL 1M Sodium Acetate, 200 µL 0.5M EDTA (Sigma-Aldrich E6758), 100µL 
1M L-cysteine (Sigma-Aldrich C7352), 100 µL 300 μg/ml Papain (Sigma-Aldrich P4762), 18.6 
mL 55nM Citric Acid/150 mM Sodium Chloride pH 7.0 in addition to the 1,9-
dimethylmethylene blue (DMMB) dye (for 1 liter: 21 mg DMMB (Sigma-Aldrich 341088), 5 mL 
100% ethanol (Sigma-Aldrich E7023), 2 g sodium formate (Sigma Aldrich 71539), 800 mL 
water,  ~200 mL formic acid (Sigma-Aldrich F0507) for pH adjust to 1.5, adjust to 1 L total 
volume with water (protect from light and lower temperatures). ECM digestion buffer was added 
to cell culture plate wells and incubated at 37°C (non-CO2 incubator) for 6 hours before sample 
collection and DMMB assay. Standard curve were created using known concentrations of 
chondroitin sulfate in a serial dilution. Total GAG content was normalized to DNA measured by 
the Picogreen assay.  
   
 25 
3.7 STATISTICAL ANALYSIS 
Statistical analysis was performed using the software R. The statistical tests performed for the 
results include: Student’s one-sample T-test (when assumptions are met), Student’s paired T-test, 
and Wilcoxon Signed Rank test. All statistical tests were two-tailed tests. The assumptions of 
Student’s T-test include equality of variance between arms/groups and Gaussian-ness/normality 
or residuals. These assumptions were checked using plots of residuals vs. fitted values and 
Quantile-Quantile (Q-Q) plots of standardized residuals for the data for each outcome measure.  
The regression diagnostics output four plots: Residuals vs. Fittted, Q-Q Plot of Standardized 
Residuals, Scale-Location Plot, and Leverage plots. The scale-location plot is in the upper left 
displays the residual errors plotted versus their fitted values. For the equality of variance 
assumption to be met, the residuals should be randomly distributed around the horizontal line 
representing a residual error of zero meaning there should not be skewedness or a trend in the 
distribution of points. Since any generated data is equal to signal measured plus noise (also 
known as residual = yi – ŷ) and bias, the Q-Q plot of residuals should have most of the points 
falling on or near the line for the Gaussian-ness of residuals assumptions to be met. The scale-
location plot is in the bottom showing the square root of the standardized residuals against fitted 
values with no obvious trend in the distribution of points. The constant leverage plot in the 
bottom right discloses more details about each datum and can help identify outliers. ‘*’ indicates 
significance (p-value less than 0.05). 
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3.7.1 Statistical Analysis: PG Synthesis 
For the PG Synthesis data, there appears to be a leverage point in the upper right of the Q-Q plot 
of residuals and residuals vs. fitted values plot (Figure 6). The range of the variances is a little 
troubling due to this leverage point. The rest of the data in the Q-Q plot of residuals appears to be 
Gaussian such that the normality of residuals assumption is roughly met. The other data in the 
residuals vs. fitted plot appears to be somewhat acceptable for the equality of variance 
assumptions. However, normalizing each senescent sample to the control sample from the same 
patient reduced this variance by quite a bit (Figure 6B). Therefore, it is a rough assumption that 
normalizing each senescent sample contributed to reducing the influence of the potential 
leverage points.  
To remain conservative, a non-parametric Wilcoxon Signed Rank test was performed. 
The null hypothesis is there is no difference in the mean of PG synthesis normalized to DNA 
between the senescent disc cells and non-senescent, control disc cells (means are equal). The 
alternative hypothesis is there is a difference between the mean of PG synthesis normalized to 
DNA between the two groups (means are not equal such that the difference is non-zero).  
For the ratio PG synthesis data, the null hypothesis is the mean ratio of senescent to 
control PG synthesis normalized to DNA is equal to one while the alternative is that the mean 
ratio not equal to one. 
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(A) Regression diagnostics for the total GAG content for senescent and control samples. (B) Regression 
diagnostics for the ratio of senescent to control samples (total GAG content). A datum was entered for one hNP 
sample for data we had collected for the linear model of GAG ratio (senescent to control) vs. cell type as represented 
by the rightmost point in the Residuals vs. Fitted plot. 
Figure 6. Regression diagnostics for GAG (DMMB) assay with senescent and non-senescent control hAF 
samples (n=3).  
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3.7.2 Statistical Analysis: PCR for Anabolic Genes 
The equality of variance assumption was met for all anabolic genes for hAF (Figure 7) and hNP 
(Figure 8) in the exponential scale (ΔCt). The normality of residuals assumption was 
approximately met for hAF (Figure 7) and hNP (Figure 8) in the exponential scale (ΔCt). 
However, transforming to the linear scale makes the distribution of the residuals more non-
Gaussian and variances more unequal (Figure 9 and 10). Essentially, normalizing to the 
calibrator sample is a similar transformation to the ratio mentioned for the statistical analysis of 
PG synthesis where two sets of values for two conditions becomes one set of values for one 
normalized condition (senescent to control). Therefore, the calibrator (control) samples in 
relative quantitative RT-PCR are denoted a value of 1 and as such causes the inequality of 
variances and non-Gaussian-ness of residuals in regression diagnostics. With this caveat, the 
assumptions for the t-test are met in the exponential scale, but not in the linear scale by the 
nature of the 2ΔΔCt approximation method [82]. Since this method is widely accepted for 
analyzing relative gene expression, such scrutiny of the t-test assumptions may not be required in 
this particular case. Overall, due to the previously established 2ΔΔCt approximation method, 
Student’s paired t-test was used for the relative expression (2ΔΔCt) values for each condition. The 
null hypothesis is the mean difference between the senescent and control groups for relative gene 
expression is zero. Of course, this is somewhat arbitrary due to calibrator/control samples being 
assigned a value of 1. Therefore, the null hypothesis may instead be taken as the mean relative 
gene expression for the senescent is equal to one (and alternative is that the mean is not equal to 
one).  
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Alternatively, the mean ΔΔCt can be used in the null hypothesis where the mean ΔΔCt 
between treated and calibrator sample is zero for a one-sampled T-test. Also, the ΔCt values can 
be compared between treated and calibrator samples such that the null hypothesis for a paired T-
test is the mean difference between ΔCt values is equal to zero.  
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Figure 7. Regression Diagnostics for ΔCt values for hAF senescent and control samples for anabolic genes 
(exponential scale). 
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Figure 8. Regression Diagnostics for ΔCt values for hNP senescent and control samples for anabolic genes 
(exponential scale). 
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Figure 9. Regression diagnostics for relative gene expression (2ΔΔCt) for hAF senescent and control 
samples for anabolic genes (linear scale) 
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Figure 10. Regression diagnostics for relative gene expression (2ΔΔCt) for hNP senescent and control 
samples for anabolic genes (linear scale) 
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3.7.3 Statistical Analysis: PCR for Catabolic Genes 
The regression diagnostics for PCR with catabolic genes shows the same result as PCR with 
anabolic genes. The assumptions are met quite well in the exponential scale (Figure 11), but not 
as much in the linear scale (Figure 12). Overall, due to the previously established 2ΔΔCt 
approximation method, Student’s paired t-test was used for the relative expression (2ΔΔCt) values 
for each condition.  
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Figure 11. Regression diagnostics for ΔCt values for hNP senescent and control samples for catabolic 
genes (exponential scale). 
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Figure 12. Regression diagnostics for relative gene expression (2ΔΔCt) for hNP senescent and control 
samples for catabolic genes (linear scale). 
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3.7.4 Statistical Analysis: ELISA (Catabolic) 
The regression diagnostics for MMP-1 (Figure 13) and MMP-3 (Figure 14) show the equality of 
variance assumption (residual vs. fitted plot) is met, but the Gaussian-ness of residuals 
assumption is not met (Q-Q plot of residuals).  Therefore, for MMP-1 and MMP-3, the non-
parametric alternative to Student’s paired T-test. Wilcoxon Signed Rank test was used over the 
paired T-test.  
The regression diagnostics for IL-6 (Figure 15) and IL-8 (Figure 16) show the equality of 
variance assumption (residual vs. fitted plot) is met as well as the Gaussian-ness of residuals 
assumption (Q-Q plot of residuals).  Therefore, for MMP-1 and MMP-3, the non-parametric 
alternative to Student’s paired T-test, Wilcoxon Signed Rank test was used over the paired T-
test.  
The null hypothesis was there is no difference in the mean protein level (MMP-1, MMP-
3, IL-6, IL-8) between senescent and control samples. The alternative was there is a difference 
between mean protein levels for the two groups. 
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Figure 13. Regression diagnostics for MMP-1 ELISA for hNP senescent and control conditioned media 
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Figure 14. Regression diagnostics for MMP-3 ELISA for hNP senescent and control conditioned media 
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Figure 15. Regression diagnostics for IL-6 ELISA for hNP senescent and control conditioned media 
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Figure 16. Regression diagnostics for IL-8 ELISA for hNP senescent and control conditioned media 
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3.7.5 Statistical Analysis: Western Detection of Aggrecan 
The regression diagnostics for the densitometry of the ADAMTS-generated (Figure 17) and 
MMP-generated (Figure 18) aggrecan fragments detected by Western were quite exceptional in 
terms of meeting the T-test assumptions of equality of variance (residuals vs. fitted plot) and 
normality of residuals (normal Q-Q plot of residuals). Therefore, Student’s one-sample T-test 
was performed. The null hypothesis was there is a difference of zero between the mean 
ADAMTS-generated and MMP-generated aggrecan fragments from the senescent and control 
samples. The alternative hypothesis was there is a difference. For the ratio, the null hypothesis is 
that the mean ratio of senescent to control is equal to one while the alternative hypothesis is that 
the ratio of senescent to control is not equal to one. 
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Figure 17. Regression diagnostics for ADAMTS-generated fragment from Western detection of Aggrecan 
for hNP senescent and control conditioned media (ratio of senescent to control). 
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Figure 18. Regression diagnostics for MMP-generated fragment from Western detection of Aggrecan for 
hNP senescent and control conditioned media (ratio of senescent to control). 
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3.7.6 Statistical Analysis: Inflammation Antibody Array 
The regression diagnostics show some inequality of variance (residuals vs. fitted), but 
approximately Gaussian residuals other than the tails (Q-Q plot) (Figure 19). However, besides 
the few potential leverage points, the assumptions are very roughly met such that Student’s one-
sample T-test is somewhat appropriate to perform. For the ratio, the null hypothesis is that the 
mean ratio of senescent to control is equal to one while the alternative hypothesis is that the ratio 
of senescent to control is not equal to one. 
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Figure 19. Regression diagnostics for Inflammation Antibody Array for hNP senescent and control 
conditioned media (ratio of senescent to control) for all targets. 
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3.7.7 Statistical Analysis: MMP Antibody Array 
The regression diagnostics show some equality of variance (residuals vs. fitted) and 
approximately Gaussian residuals other than the tails (Q-Q plot) (Figure 20).  The assumptions 
appear to be met such that Student’s one-sample T-test is appropriate to perform. For the ratio, 
the null hypothesis is that the ratio of senescent to control is equal to one while the alternative 
hypothesis is that the ratio of senescent to control is not equal to one. 
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Figure 20. Regression diagnostics for MMP Antibody Array for hNP senescent and control conditioned 
media (ratio of senescent to control) for all targets. 
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3.7.8 Statistical Analysis: MMP Enzymatic Activity Assay 
The regression diagnostics for MMP enzymatic activity assay revealed an approximately 
normality of residuals and equality of variance for hAF and hNP samples (Figures 21 and 22) 
such that Student’s paired T-test is appropriate to perform. The null hypothesis is that the mean 
MMP enzymatic activity of senescent disc cells equals the man MMP enzymatic activity of 
untreated, non-senescent control disc cells. The alternative hypothesis is that the mean MMP 
activity of senescent disc cells is not equal to the mean MMP activity of non-senescent control 
disc cells. 
 
 
 
 
 
   
 50 
 
Figure 21. Regression diagnostics for MMP Enzymatic Activity for hAF senescent and control conditioned 
media (ratio of senescent to control) for all targets. 
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Figure 22. Regression diagnostics for MMP Enzymatic Activity for hNP senescent and control conditioned 
media (ratio of senescent to control) for all targets. 
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3.7.9 Statistical Analysis: GAG (DMMB) Assay 
The regression diagnostics were acceptable with rough equality of variance and normality of 
residuals with a potential leverage point (Figure 23). Due to the paired nature of the hAF and 
hNP isolated from the same patients, the potential leverage point was not removed from the data 
set. Therefore, with assumptions being roughly met, Student’s one-sample T-test was performed. 
The null hypothesis was there is a difference of zero between the mean total GAG content 
normalized to DNA from the senescent and control samples. The alternative hypothesis was 
there is a difference. For the ratio, the null hypothesis is that the ratio of senescent to control is 
equal to one while the alternative hypothesis is that the ratio of senescent to control is not equal 
to one. 
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Figure 23. Regression diagnostics for GAG assay Activity for hAF and hNP senescent and control 
conditioned media (ratio of senescent to control) for all targets. 
   
 54 
4.0  RESULTS 
4.1 CONFIRMATION OF SENESCENCE INDUCTION 
4.1.1 SA-β-Galactosidase Staining 
To induce senescence, human disc cells were exposed to hydrogen peroxide for 2 hours then 
changed to regular media F-12 10% FBS 1% PS, split onto new plates, incubated overnight, 
treated with hydrogen peroxide again for two hours, changed to fresh media, and incubated for 4 
days before sample collection and analysis to allow enough time for the development of SASP. 
To confirm senescence, SA β-gal staining was performed, and the results showed that a majority 
of the hydrogen peroxide treated cells were positive for SA β-gal activity along with enlarged 
flattened morphology (Figure 24). The hydrogen peroxide-treated cells also exhibited growth 
arrest as assessed qualitatively via microscopy (Figure 24). These features are consistent with 
those seen in senescent cells, which reportedly have the characteristics of enlarged morphology, 
increased senescence-associated β-galactosidase activity, nuclear DNA damage foci, p16 
expression, and changes in chromatin organization and gene expression [67]. 
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Compared to untreated control (left), nearly all the cells in human disc monolayer cultures consecutively 
exposed to 0.5mM H2O2 entered senescence (right), as evidenced by SA β-gal activity staining (blue) and cell 
morphological changes (flat pancake appearance). Representative images taken from one donor (n=4). 
Figure 24. Oxidative stress-induced disc cellular senescence. 
4.2 MATRIX ANABOLISM 
4.2.1 PG Synthesis 
To assess matrix anabolism, 35S-sulfate incorporation assay for hAF and hNP senescent and 
untreated control cells was performed.  Senescent disc cells showed a non-significant decreasing 
trend of PG synthesis by about 2.5x compared to untreated, non-senescent control cells (Figure 
25A) with a mean ratio of approximately 0.6 for senescent to control (Figure 25B). This non-
significant result trends toward the expected outcome of senescent disc cells in producing less 
new PG matrix compared to non-senescent control cells proposed in specific aim 1.  
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(A) H2O2–induced senescent disc cells incorporated 5100 + 750 fmoles 35S-sulfate/mg DNA, about two-
fold lower than that seen in untreated non-senescent disc cells (12200 + 3800). (B) Ratio of senescent to control. 
Dotted line represents ratio of 1 denoting no change. Blue square represents mean.  Error bars represent SEM (n=3). 
Figure 25. Oxidative stress-induced senescent disc cells displayed reduced PG synthesis. 
   
 57 
 
4.2.2 PCR Anabolic Genes 
To assess matrix anabolism, qRT-PCR was performed for key matrix component genes 
Aggrecan, Collagen Type I, Collagen Type II, Hyaluronan and Proteoglycan Link Protein 1 
(HAPLN1), Versican. In hAF, collagen type I (p = 0.02936) expression decreases by 32.5% 
(Figure 26A) in senescent cells compared to control cells. In hNP, collagen type II (p = 0.03148) 
expression increases by 10-fold (Figure 26B) in senescent cells compared to control cells. 
Senescent hAF cells also trended towards an increase of collagen type II expression (non-
significant, p = 0.1783), which may be non-significant due to the large variance in the donor 
samples for collagen type II expression compared to the small variance in the donor samples for 
collagen type I expression.  The remaining matrix genes aggrecan, HAPLN-1, and versican 
remained relatively unchanged in senescent hAF and hNP cells compared to their non-senescent 
counterparts, with the exception of aggrecan trending towards increased expression in hAF 
(Figure 26). The expected outcome was decreased anabolic matrix gene expression, which is not 
the case observed for aggrecan, link protein, and versican. In hAF, there appears to be a 
divergence in collagen type I (decrease) and collagen type II (increase) expression while the only 
change for hNP is increase in collagen type II expression. 
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(A) hAF. (B) hNP. Aggrecan, Link Protein, and Versican matrix genes remain relatively unchanged for 
both hAF and hNP. Dotted line represents ratio of 1 denoting no change. Blue square represents mean.  Error bars 
represent SEM (hAF n=2, hNP n=3 to n=6). 
Figure 26. Oxidative stress-induced senescent disc cells displayed decreased Collagen Type I in hAF and 
increased Collagen Type II in hNP. 
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4.3 MATRIX CATABOLISM 
4.3.1 PCR Catabolic Genes 
To assess matrix catabolism, qRT-PCR was performed for key SASP catabolic factors, MMP-1, 
MMP-3, IL-6, IL-8, ADAMTS-4, ADAMTS-5, TIMP-1, and TIMP-3.  mRNA levels of MMP-1 
(23-fold, p=0.01921), MMP-3 (20-fold), IL-6 (6-fold), IL-8 (9-fold) were higher in senescent 
disc cells while ADAMTS4 (1.01-fold), ADAMTS5 (0.93-fold), TIMP1 (1.7-fold), TIMP3 (1.6-
fold) remained relatively unchanged compared to control hNP cells (Figure 27). Only the MMPs 
were transcriptionally upregulated in senescent disc cells while ADAMTS mRNA levels 
remained relatively unchanged compared to untreated, non-senescent control cells.  
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Compared to non-senescent disc cells, senescent disc cells greatly up-regulated mRNA expression of 
MMP-1, MMP-3, IL-6 and IL-8. Dotted line represents ratio of 1 denoting no change. Blue square represents mean.  
Error bars represent SEM (n=4). 
Figure 27. Oxidative stress-induced senescent hNP cells enhanced expression of catabolic factors. 
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4.3.2 ELISA for Catabolic Factors 
To assess the protein levels of the most upregulated catabolic factors, ELISA was performed for 
IL-6, IL-8, MMP-1, and MMP-3 in the conditioned media of senescent and non-senescent 
control hNP cell cultures. Similar to their mRNA expression, MMP-1 (p = 0.008516) and MMP-
3 proteins (p = 0.0145) had the greatest increases in secretion from senescent hNP cells 
compared to control cells with 0.02 pg/mL per cell for senescent compared to undetectable for 
control for MMP-1 and 0.8 pg/mL per cell (normalized to cell number) for senescent cell media 
compared to 0.01 pg/mL per cell for control media for MMP-3 (Figure 28). This result supports 
the hypothesis of Specific Aim 2 that senescent cells secreted increased levels of catabolic 
factors.  
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Compared to non-senescent disc (hNP) cells, senescent disc cells greatly increased secretion of catabolic 
proteins MMP-1, MMP-3, IL-6 and IL-8. Blue square represents mean.  Error bars represent SEM (n=4). 
Figure 28. Oxidative stress-induced senescent disc cells secrete catabolic factors. 
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4.3.3 Western Blot for Detection of Aggrecan 
To determine whether senescent disc cells produce intact or fragmented aggrecan matrix,  
Western blot was performed. Western analysis revealed greater levels of ADAMTS-generated 
(Figure 29B) and relatively unchanged MMP-generated (Figure 29C) proteolytic aggrecan 
fragments as a result of cleavage in the aggrecan interglobular domain (IGD) in the conditioned 
culture media of H2O2–induced senescent hNP cells compared to those of nonsenescent hNP 
cells.  In contrast, the levels of aggrecan IGD proteolytic fragments were relatively unchanged in 
the conditioned media of senescent hAF cell culture compared to nonsenescent AF cell culture 
(Figure 29). 
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(A)Western blot for detection of Aggrecan (Anti-Agc) in hAF and hNP senescent and negative control conditioned 
media samples. ADAMTS-generated and MMP-generated fragments indicated. (B) and (C) Quantification of (A) 
using densitometry represented as relative ratio of volumes for senescent to control CM. Dotted line represents ratio 
of 1 denoting no change. Blue square represents mean.  Error bars represent SEM (n=3). 
Figure 29. Oxidative stress-induced senescent disc cells produced more ADAMTS-generated aggrecan 
fragments. 
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4.3.4 Inflammation and MMP Antibody Arrays 
To assess the secretome profile of senescent disc cells, inflammation and MMP arrays were 
performed on the conditioned media of senescent and non-senescent control hNP cell cultures. 
Inflammation (Figure 30B) and MMP (Figure 30A) antibody arrays showed elevated levels of 
many pro-inflammatory cytokines (IL-6, IL-8, PDGF-BB, GCSF), chemokines (EOTAXIN-2, 
IP-10, RANTES) and MMPs (MMP-3, MMP-10, TIMP-2) in the conditioned media of senescent 
hNP cells. Intriguingly, MMP-1 was secreted more from senescent cells as detected by ELISA, 
however this increase was not detected by the MMP antibody array perhaps indicating lack of 
sensitivity of the antibody array compared to ELISA. Another possibility for this inconsistency 
may be the variation between samples isolated from patients with variable age, sex, diagnosis, 
and degeneration grade. 
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(A) MMP and (B) Inflammation arrays. Error bars represent SEM (n=4). Significance Codes: ‘**’ 0.01 ‘*’ 0.05 
Figure 30. Quantified MMP and Inflammation secreted proteins levels are increased in oxidative-stress 
induced senescent human NP cells. 
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4.3.5 MMP enzymatic activity assay 
To evaluate the activity of the MMPs secreted from senescent disc cells, MMP enzymatic 
activity was performed on conditioned media samples using a fluorogenic substrate. For all 
samples, there was a lack of MMP enzymatic activity (Figure 31C) from cleavage product 
fluorescence indicating any trends seen here may only represent changes in noise or background 
and not meaningful changes between experimental conditions (Figure 31A and 31B). These non-
significant changes must be confirmed with modified experimental protocols as these were the 
initial preliminary experiment for this type of outcome measure. The signal after background 
subtraction was not strong as it the samples’ signals were similar in magnitude to the blank’s 
signal. For samples positive for MMP enzymatic activity, there should be a linear increase in 
RFU with time with RFU values into the thousands by the last 30 minutes of the assay. However, 
all samples plateau between 50-100 RFU by the 5 or 10 minute time point (Figure 31C) 
suggesting a lack of MMP enzymatic activity in all samples. MMPs may have increased mRNA 
expression and protein secretion; however, there is a lack of MMP enzymatic activity perhaps 
suggesting post-translational regulation.   For example, the MMPs secreted into conditioned 
culture media were in the inactive preforms. 
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(A) hAF MMP enzymatic activity (mM Fluorescent Product/min). (B) hNP MMP enzymatic activity (mM 
Fluorescent Product/min). (C) Cleavage Product Fluorescence vs. Time (min). Blue square represents mean. Error 
bars represent SEM (n=3). 
Figure 31. Oxidative-stress induced senescent disc cells display relatively unchanged MMP enzymatic 
activity. 
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4.4 TOTAL MATRIX PROTEOGLYCAN CONTENT 
4.4.1 GAG (DMMB) Assay 
To assess the total GAG content representative of the total PG in hAF and hNP, DMMB assay 
was performed for senescent and non-senescent control cells. The total GAG content decreased 
in senescent hAF and hNP cell cultures, the latter was statistically significant while the former 
was not (Figures 32 and 33). 
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(A) hAF (B) hNP. Normalized to DNA amount. Blue square represents mean. Error bars represent SEM (n=3). 
Figure 32. Oxidative-stress induced senescent disc cells display decreased total GAG content. 
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Ratio of Senescent to Control (Total GAG content normalized to DNA). Dotted line represents ratio of 1 denoting 
no change. Blue square represents mean. Error bars represent SEM (n=3). 
Figure 33. Oxidative-stress induced senescent disc cells exhibit a decreased ratio of total GAG content 
relative to untreated, non-senescent control cells. 
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5.0  DISCUSSION 
5.1 SUMMARY 
The goal of my thesis project was to determine if senescent disc cells exhibit perturbed matrix 
homeostasis.  The strong oxidant H2O2 was used to induce senescence of human disc cells which 
showed dramatically perturbed matrix homeostasis, including decreased capacity for new PG 
synthesis (Figure 25) as well as enhanced expression and secretion of key inflammatory 
cytokines, chemokines, and matrix proteinases.  These are the catabolic factors which constitute 
the hallmark feature of senescent fibroblasts (Figures 27-28, 30) previously termed senescence 
associated secretory phenotype (SASP) [47, 84].  Age-dependent accumulation of senescent cells 
in various organs is thought to disrupt tissue structure and function, and promote aging due at 
least in part to their SASP.  My study showed that stress-induced senescent human disc cells also 
acquired SASP-like phenotype (Figures 24, 27-28, 30) which may have profound catabolic 
effects on neighboring cells and the extracellular matrix. Consistent with this idea was the 
observation of enhanced aggrecanolysis (Figure 29) and decreased total GAG content (Figures 
32 and 33) in senescent disc cell culture.  Disc senescent cells contribute to perturbed 
extracellular matrix homeostasis through the acquisition of SASP, reduced matrix synthesis, 
increased matrix degradation. 
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5.2 DISC MATRIX ANABOLISM 
For anabolism, PG synthesis (Figure 25) and anabolic matrix relative gene expression (Figure 
26) were analyzed to detect differences in senescent hAF cells compared to untreated, non-
senescent control cells. Senescent cells exhibited a decreasing trend for newly synthesized PG 
which indicates a reduced capacity of senescent disc cells to produce new matrix to maintain disc 
matrix homeostasis to offset the process of normal aggrecan turnover. This decreasing trend for 
PG synthesis also held for hNP for a sample size of 1 patient’s donor cells (data not shown). 
Overall, the PG synthesis results support the hypothesis of decreased anabolism in senescent disc 
cells for Specific Aim 1.  
The major collagen in AF tissue, collagen type I has been shown to express at decreasing 
levels with age in disc [7].  Decrease in collagen type I expression in senescent hAF cells was 
consistent with our hypothesis in Specific Aim 1. However, the increase in collagen type II for 
both hAF and hNP was unexpected as decreased anabolic matrix gene expression was predicted. 
One possibility is the post-transcriptional or post-translational regulation of collagen type II may 
differ from collagen type I [85-87].  Perhaps the changes in collagen type I and II expression are 
merely indicative of there being more collagen in hAF than hNP. The relatively unchanged 
expression of aggrecan, versican, and link protein is not consistent with the decreased PG 
synthesis in senescent hAF cells result, implying post-transcriptional and or post-translational 
regulations [19, 88-93] which account for decreased translation, export, and assembly.    
Collagen type I transitions to greater proportions collagen type II from outer AF to inner 
AF and NP. During early stages of degeneration, the amount of the major collagen types I and II 
are increased along with the minor types (III, V, VI). During degeneration, the ratio of type I-to-
type II collagen increases in the inner AF and NP, which may result from an increase in type I 
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collagen or a decrease in type II collagen [94]. Taking this into consideration when interpreting 
the decrease in collagen type I and increase in collagen type II for hAF gene expression, this 
outcome is contradictory to the increasing type I-to-type II collagen ratio in degenerated inner 
AF and NP and may imply a shift to a more chondrocytic phenotype (more similar to NP). 
However, the increase in collagen type II mRNA expression in senescent cells compared to 
control cells in hNP is intriguing and contradictory to my hypothesis as it would be beneficial to 
the NP function of resisting compressive forces.   Further experiments are needed to confirm 
whether the collagen type I and II protein levels correlate with their mRNA expression levels.  If 
confirmed, this would suggest that the whole disc structure may be less efficient for its native 
function in resisting tensile strain due to the shift of both the hAF and hNP towards a more 
collagen type II-rich, chondrocytic phenotype.   
5.3 DISC MATRIX CATABOLISM 
For hNP senescent cells, expression of SASP factors IL-6, IL-8, MMP-1, MMP-3 [67] were 
found to be upregulated both at the levels of transcription (Figure 27) as well as protein (Figure 
28). The relative mRNA gene expressions of ADAMTS-4 and ADAMTS-5 as well as the 
catabolic tissue inhibitors TIMP-1 and TIMP-3 in hNP senescent cells did not change much, 
possibly due to post-translational modulation rather than transcriptional regulation [95-98]. 
Inflammation and MMP antibody arrays revealed that senescent disc cells secrete many pro-
inflammatory cytokines, chemokines, and remodeling factors characteristic of SASP [67, 99]. 
Overall, the catabolic gene expression, ELISA, and inflammation and MMP antibody array 
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findings supported the hypothesis of increased catabolism in senescent disc cells proposed in 
Specific Aim 2. 
Western blot for aggrecan (Figure 29) revealed increased ADAMTS-generated aggrecan 
fragments (Figure 29B) and relatively unchanged MMP-generated aggrecan fragments in 
senescent disc cell cultures. These results are intriguing because   MMP-1 and MMP-3 mRNA 
and protein expressions increased in senescent disc cells while ADAMTS-4 and ADAMTS-5 
mRNA expression remained unchanged.   It is likely that in cell cultures there may be post-
translational regulation influencing the enzymatic activity of the aggrecanases (becoming 
activated) and MMPs (remaining inactive) [95, 96].   In fact, MMPs are secreted in a latent, 
inactive pro-form, and my assessment of MMP enzymatic activity showed minimal enzymatic 
activity in both senescent and control hNP cell conditioned media (Figure 30). This result still 
seems contradictory to the MMP-generated aggrecan fragments detected by Western blot 
indicating some enzymatic activity in both senescent and control disc cells conditioned media 
despite the lack of a difference between conditions.  However, TIMP inhibition can confound the 
results of the MMP enzymatic activity assay as these catabolic inhibitors regulate MMPs and 
ADAMTSs as has been documented in disc specifically [100-103].  TIMP inhibition may be 
masking the ability for MMP activity assay to detect any fluorogenic product cleavage from both 
senescent and control disc cell conditioned media samples. Another possibility for the lack of 
observed MMP enzymatic activity may be the treatment with 500 µM hydrogen peroxide as 
greater than 50 µM of ROS has been previously reported to inhibit MMP activity in vitro [104-
107], however this seems unlikely as the hydrogen peroxide media was removed after two hours 
and replaced with fresh media. An additional possibility for the lack of MMP activity may be the 
late stage attenuation of SASP by microRNAs, mir-146a and mir-146b, reported to decrease NF-
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κB activity after secretion from senescent cells in vitro after IL-6 and IL-8 secretion peaks [47, 
48, 99, 108]. Overall, this Western blot finding supported the hypothesis that senescent cells 
have increased catabolism of disc matrix for Specific Aim 2 while the MMP activity finding 
does not support this hypothesis. It must be viewed as inconclusive at this time. There may be a 
basal level of MMP activity for aggrecan proteolysis while MMPs are upregulated in senescent 
cells in this latent, inactive pro-form such that there was not a higher amount of MMP-generated 
aggrecan fragments detected in senescent disc cells. 
5.4 DISC TOTAL MATRIX PROTEOGLYCAN CONTENT 
Total PG matrix content was measured using the DMMB assay for GAG.   There was a 
significant decrease in total GAG content from senescent hNP cells compared to non-senescent 
control cells (Figures 32 and 33).  The net GAG content was determined by matrix homeostatic 
balance, i.e., rates of catabolism vs anabolism.  My  anabolic and catabolic findings along with 
this decreased total GAG content of the disc matrix supports the idea that senescent disc cells 
acquire an imbalance of disc matrix homeostasis.  Overall the findings support the central 
hypothesis of decreased anabolism and increased catabolism in senescent disc cells.  
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5.5 LIMITATIONS 
One of the biggest limitations in the disc field is the lack of fresh control specimens from healthy 
human donors to compare with degenerated discs. The disc specimens isolated from surgeries on 
individuals with low back pain are likely degenerative. Also, the frequency of human disc 
specimen availability, amount of disc tissue and cells isolated from those tissues, and the 
generally slower growth rate than healthy animal models (rabbits, cows…) provides unique 
challenges to studying the disc in human. Another caveat is the growth condition.  Naturally, the 
disc cells reside in a low oxygen environment, and thus culture of disc cells at atmospheric 
oxygen (20%) in normal incubators is not ideal. However, this is often done in the disc field due 
to cost constraint.   Recently, disc cell culture research in my laboratory is moving toward using 
hypoxic chambers to better mimic the physiological condition of disc tissue.  More specifically 
to this study, human specimens from patients are widely variable due to the inability to match for 
age, sex, degeneration grade without a large pool of donors to choose from. This variability 
between donors generally translates to high variances between samples for all outcome 
measures. The small sample size is quite limiting for statistical power such that a sample size of 
5 or 6 is required to see any significant change for such variable samples.  
The next limitation would be the monolayer cell culture that all these experiments were 
performed in. Our lab utilized 3D cell cultures with alginates beads primarily for rabbit NP cell 
as the large cell numbers needed for enough beads for experiments is attainable for rabbit, but 
not as easily for human degenerated samples. Disc cells better retain their phenotype when in 3D 
culture compared to monolayer as 3D is more similar to their native environment.  
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These disc primary cells are further limited in that their phenotype begins to shift by passage 3 
thus proliferation and expansion is limited for primary cells from each donor constraining the 
amount of experiments that can be performed. 
5.6 FUTURE DIRECTIONS 
A stress control should also be performed to compare ER stress via drugs like thapsigargin, 
tunicamycin, bortezomid, and cyclosporine in order to compare to the mitochondrial stress of 
H2O2 to confirm these results are specific to oxidative stress rather than stress in general. This 
may be monitored with gene expression of Xbp1 (spliced variant) and C/EBP Homologous 
Protein (CHOP) via qRT-PCR to differentiate H2O2 (mitochondrial) stress response from other 
stress responses (ER stress).  
For current experiments, further work will increase the sample size of outcome measures 
such as PG synthesis, anabolic PCR, total GAG content, western for aggrecan proteolysis to 
further corroborate the findings observed so far. Western blot for ADAMTS-4 and ADAMTS-5 
in conditioned media from senescent and non-senescent cell is needed to further elucidate the 
specific ADAMTS is primarily responsible for the proteolytic cleavage of aggrecan in the disc 
matrix. Western blot will also be performed on conditioned media for TIMPs such as TIMP-1, 
TIMP-2, and TIMP-3 for comparison of these protein levels secreted from senescent disc cells 
and control cells. TIMP inhibition assay quenched fluorescent substrate assay) should also be 
performed to determine the amount of inhibition in a conditioned media sample to further 
elucidate the lack of MMP activity in the senescent cell conditioned media samples.  
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To further examine the changes in collagen type I and II metabolism in senescent disc 
cells, collagen synthesis with radiolabeled proline (3H-L-Proline) will be performed and 
compared to the PG synthesis findings. Also, to corroborate the decrease of collagen type I in 
hAF and increase in collagen type II in hAF and hNP samples, anti-collagen antibodies can be 
used to assay collagen degradation [109, 110] as well as more qRT-PCR to increase the sample 
size. The expected outcomes would be decreased collagen synthesis and increased collagen 
degradation generated in senescent disc cells compared to non-senescent control cells.  
Future in vivo experiments are needed to assess similar outcome measures as performed 
in this in vitro study from the discs from an accelerated aging (progeroid) mouse model 
compared to old and young wild type mice to confirm the role of disc cellular senescence in 
matrix homeostatic imbalance.  More important, in vivo studies are also needed to investigate 
whether clearance of senescent cells in accelerated aging mice or naturally aging mice [71] 
affects disc tissue structure and function.   
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6.0  PUBLIC HEALTH SIGNIFICANCE 
By 2050, the world population is estimated to have 1.5 billion of individuals ages 65 and older 
compared to 524 million in 2010 [32, 33]. Aging is the largest single risk factor for intervertebral 
disc degeneration (IDD), as disc matrix proteoglycan (PG) is invariably and progressively 
depleted with age [76].  Dysregulated disc cells are thought to drive age-associated disc PG loss 
through a combination of reduced capacity to synthesize matrix PG and increased production of 
proteolytic enzymes to breakdown matrix [111].  The link between aged degenerative discs and 
cellular senescence has been previously observed in human discs [74, 75], but it remains 
unknown if senescent disc cells are phenotypically different from their non-senescent counterpart 
in terms of matrix homeostasis.  
How aging disrupts disc matrix homeostasis leading to PG loss and IDD is not clearly 
understood.  Implicating cellular senescence (and SASP development) as a driver of disc PG loss 
and IDD will offer novel opportunities for targeted therapy to prevent or treat IDD, which would 
have a tremendous public health impact in preventing or limiting chronic low back pain.  
Hence, understanding the biology of disc aging is critical in developing effective 
therapeutic interventions to treat age-related IDD disorders.  This is imperative because of the 
growing aging population which is expected to bring great burdens and challenges from the 
many age-related diseases.  This thesis research initiated and established a basic framework of 
how aging affects disc health through the action of senescent disc cells on matrix metabolism.  
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